The goal is to support commercial manufacturing of LNP-based therapeutics on a large scale, making them more economically feasible for healthcare systems, said the partners.
NANOus is a flexible small-to-high-volume manufacturing device designed for aseptic GMP-compliant nanoencapsulation of APIs, based on LEON’s proprietary NANOnow technology.
The two Germany based companies, in action at CPHI in Frankfurt this week, said they are in the process of assembling the market-ready device, which they claim will enable rapid and cost-efficient, seamless scale-up for production of LNP-encapsulated therapeutics. “NANOus can enable continuous manufacturing of several million vaccine doses per day.”
By enabling easy scale-up, process analytical technology (PAT) and GMP-compliance, NANOus targets unmet needs of pharma and biotech industries and CDMOs, according to the two entities.
The collaboration leverages Harro Höfliger’s mechanical engineering and process capabilities while LEON is bringing its core technology platform to the deal.
Andrea Cusack, CEO of leon-nanodrugs, said that Harro Höfliger has an extensive track-record of successfully bringing new pharmaceutical production processes from lab-scale to commercial production, making it the ideal partner for LEON as it brings its technology to the biopharma industry.
"While the field of nanomedicine has really come to the forefront, we are aiming at unparalleled solutions to manufacturing those medicines in a very efficient and effective way. Our technology will allow much broader accessibility of mRNA vaccines, therapeutically enhanced biologics, or small molecules," she added.